<?xml version="1.0" encoding="UTF-8"?>
<data date-time-format="iso8601">
  <event start="2022-01-13T00:00:00Z" title="was published in New England Journal of Medicine on Thursday">
    Their study was published in New England Journal of Medicine on Thursday.
  </event>
  <event start="0000-00-00T00:00:00Z" title="was identified last year">
    The mutation considered in this study was identified last year as the molecular marker of artemisinin-resistant malaria.
  </event>
  <event start="0000-00-00T00:00:00Z" title="includes three days">
    The prolonged regimen which includes three days of artesunate followed by three days of dihydroartemisinin–piperaquine, has shown 2% rate of failure at day 42 in the same area.
  </event>
  <event start="0000-00-00T00:00:00Z" title="followed by three days">
    The prolonged regimen which includes three days of artesunate followed by three days of dihydroartemisinin–piperaquine, has shown 2% rate of failure at day 42 in the same area.
  </event>
  <event start="0000-00-00T00:00:00Z" title="were followed for 42 days">
    Afterwards, patients at several study sites were followed for 42 days — Pailin, Cambodia; Attapeu, Laos; Binh Phuoc, Vietnam; Shwe Kyin, Myanmar; and Pingilikani, Kenya — and for 28 days in Kinshasa, DR Congo.
  </event>
</data>
